Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

Summary

The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.

Timeline

Start

2018-08-15

Primary completion

2022-10-27

Completion

2022-10-31

Outcome

Outcome not reported

Stopped: “This trial has undergone a prespecified interim analysis which determined that this treatment provides no statistically significant delay in the onset of abnormal glucose tolerance or Type 1 Diabetes.”

Drugs

Indications